Study of Marham Kharish Jadeed (Unani Drug) in Ringworm

A Clinical Study to Evaluate the Efficacy and Safety of Marham Kharish Jadeed in the Management of Quba (Tinea Corporis) - TMKJ

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010995

Enrollment

Registered

2017-12-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- QUBA (TINEA CORPORIS)

Interventions

Intervention1: Marham Kharish Jadeed: Marham will be applied locally on the affected parts twice daily. Intervention2: Marham Kharish Jadeed: Marham will be applied locally on the affected parts twice

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having Quba (Tinea corporis) with the following signs and symptom: a.Itching b.Erythema c.Scaling of lesion d.Central clearing with peripheral raised margins 2.Patients with a mycological diagnosis of Tinea Corporis confirmed by microscopic KOH wet mount

Exclusion criteria

Exclusion criteria: 1.All other clinical types of tinea infections 2.Patients with secondary bacterial infections/ Diabetes Mellitus 3.Pregnant and lactating women 4.Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction 5.Known cases of Immunocompromised states (HIV/ AIDS, etc.) 6.History of hypersensitivity to Terbinafine and Marham Kharish Jadeed 7.Patients using the following medications: 8.Topical antifungal agent/ topical corticosteroids in treatment area within 30 days of baseline visit 9.Systemic anti-fungals within 8 weeks of baseline visit (8 months for oral Terbinafine) 10.Systemic corticosteroids within 30 days of baseline visit

Design outcomes

Primary

Measure	Time frame
1.To evaluate the efficacy of Marham Kharish Jadeed in the management of Quba (Tinea corporis) 2.To evaluate the safety of Marham Kharish Jadeed in the management of Quba (Tinea corporis)Timepoint: at baseline 2 3 & 4 week	—

Secondary

Measure	Time frame
To compare the improvement in quality of life in patients with Quba by TSSS KOH mount, IGATimepoint: at baseline 2 3 & 4 week	—

Countries

India

Contacts

Public ContactDr Arzeena Jabeen

Central Research Institute of Unani Medicine, Hyderabad

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026